Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma

Modern Pathology

Volumn 28, Issue 4, 2015, Pages 487-497

  Massi, Daniela ^a   Simi, Lisa ^b   Sensi, Elisa ^c   Baroni, Gianna ^a   Xue, Gongda ^d   Scatena, Cristian ^a   Caldarella, Adele ^e   Pinzani, Pamela ^b   Fontanini, Gabriella ^c   Carobbio, Alessandra ^f   Urso, Carmelo ^g   Mandalà, Mario ^f  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Laboratory of Molecular Pathology UO Pathological Anatomy III   (Italy)

^d FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^e Institute for Study and Cancer Prevention ISPO   (Italy)

^f PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^g SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FORMALDEHYDE; PARAFFIN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

A375 CELL LINE; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CUTANEOUS MELANOMA; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE; GENETIC SCREENING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; NRASQ61R GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; GENETICS; MELANOMA; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; SKIN TUMOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84926513938     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.137     Document Type: Article

References (29)

1. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003;3:459-465.
2. Henis YI, Hancock JF, Prior IA. Ras acylation, compartmentalization and signaling nanoclusters [review]. Mol Membr Biol 2009;26:80-92.
3. Mor A, Philips MR. Compartmentalized Ras/MAPK signaling. Annu Rev Immunol 2006;24:771-800.
4. Mandala M, Merelli B, Massi D. NRAS in melanoma: targeting the undruggable target. Crit Rev Oncol Haematol 2006; doi:10.1016/j.critrevonc.2014.05.005 (e-pub ahead of print).
5. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012;118:4014-4023.
6. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-362.
7. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013;14: 249-256.
8. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-977.
9. Mancini I, Pinzani P, Pupilli C, et al. A high-resolution melting protocol for rapid and accurate differential diagnosis of thyroid nodules. J Mol Diagn 2012;14: 501-509.
10. Johnson DB, Lovly CM, Flavin M, et al. NRAS mutation: a potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM). J Clin Oncol 2013;31:(Suppl): (abstract 9019).
11. Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012;30:2522-2529.
12. Fedorenko IV, Gibney GT, Smalley KS. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene 2013;32: 3009-3018.
13. Si L, Kong Y, Xu X, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 2012;48:94-100.
14. Akslen LA, Puntervoll H, Bachmann IM, et al. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 2008;18: 29-35.
15. Edlundh-Rose E, Egyházi S, Omholt K, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006;16:471-478.
16. McArthur G, Ribas A, Chapman PB, et al. Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation positive metastatic melanoma patients (pts) Proceedings of the American Society of Clinical Oncology, Chicago. J Clin Oncol 2011;29:3-7; (Suppl): (abstract 8502).
17. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-954.
18. Omholt K, Platz A, Kanter L, et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003;9:6483-6488.
19. Thomas NE, Edmiston SN, Alexander A, et al. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 2007;16:991-997.
20. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
21. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004;15:177-182.
22. Dadzie OE, Yang S, Emley A, et al. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis. Br J Dermatol 2009;160:368-375.
23. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013;37:61-65.
24. Pearlstein MV, Zedek DC, Ollila DW, et al. Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma. J Cutan Pathol 2014;41:724-732.
25. Menzies AM, Lum T, Wilmott JS, et al. Intrapatient homogeneity of BRAFV600E expression in melanoma. Am J Surg Pathol 2014;38:377-382.
26. Feller JK, Yang S, Mahalingam M. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. Mod Pathol 2013;26:414-420.
27. Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013;31:1767-1774.
28. Decarlo K, Yang S, Emley A, et al. Oncogenic BRAFpositive dysplastic nevi and the tumor suppressor IGFBP7-challenging the concept of dysplastic nevi as precursor lesions? Hum Pathol 2010;41:886-894.
29. van 't Veer LJ, Burgering BM, Versteeg R, et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989;9: 3114-3116.